What is Sanara Medtech Inc's earnings per share (EPS)?

Sanara Medtech Inc (SMTI) reported diluted earnings per share of $-4.36 for fiscal year 2025. This represents a -282.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sanara Medtech Inc Financials

SMTI

Source SEC Filings (10-K/10-Q) Updated Mar 24, 2026 Currency USD FYE March

This page shows Sanara Medtech Inc (SMTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 28/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Sanara Medtech Inc has an operating margin of 7.1%, meaning the company retains $7 of operating profit per $100 of revenue. This results in a moderate score of 38/100, indicating healthy but not exceptional operating efficiency. This is up from -7.8% the prior year.

Growth

Sanara Medtech Inc's revenue surged 19.0% year-over-year to $103.1M, reflecting rapid business expansion. This strong growth earns a score of 65/100.

Leverage

Sanara Medtech Inc has elevated debt relative to equity (D/E of 7.74), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Sanara Medtech Inc's current ratio of 1.80 indicates adequate short-term liquidity, earning a score of 32/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Sanara Medtech Inc has a free cash flow margin of 2.1%, earning a moderate score of 30/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Sanara Medtech Inc generates a -632.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -24.5% the prior year.

Altman Z-Score Grey Zone

1.96

Sanara Medtech Inc scores 1.96, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($158.0M) relative to total liabilities ($67.0M). This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral

4/9

Sanara Medtech Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Mixed

-0.18x

For every $1 of reported earnings, Sanara Medtech Inc generates $-0.18 in operating cash flow ($6.8M OCF vs -$37.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

1.1x

Sanara Medtech Inc earns $1.1 in operating income for every $1 of interest expense ($7.3M vs $6.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$103.1M

YoY+19.0%

5Y CAGR+45.9%

10Y CAGR+40.8%

Sanara Medtech Inc generated $103.1M in revenue in fiscal year 2025. This represents an increase of 19.0% from the prior year.

EBITDA

$11.3M

YoY+727.7%

Sanara Medtech Inc's EBITDA was $11.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 727.7% from the prior year.

Net Income

-$37.6M

YoY-288.7%

Sanara Medtech Inc reported -$37.6M in net income in fiscal year 2025. This represents a decrease of 288.7% from the prior year.

EPS (Diluted)

$-4.36

YoY-282.5%

Sanara Medtech Inc earned $-4.36 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 282.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$2.2M

YoY+1041.1%

Sanara Medtech Inc generated $2.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 1041.1% from the prior year.

Cash & Debt

$16.6M

YoY+4.4%

5Y CAGR+105.2%

10Y CAGR+57.0%

Sanara Medtech Inc held $16.6M in cash against $46.0M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+4.7%

5Y CAGR+7.8%

10Y CAGR-21.8%

Sanara Medtech Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 4.7% from the prior year.

Margins & Returns

Gross Margin

92.7%

YoY+2.1pp

5Y CAGR+3.1pp

10Y CAGR+19.2pp

Sanara Medtech Inc's gross margin was 92.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the prior year.

Operating Margin

7.1%

YoY+14.8pp

5Y CAGR+39.4pp

10Y CAGR+35.7pp

Sanara Medtech Inc's operating margin was 7.1% in fiscal year 2025, reflecting core business profitability. This is up 14.8 percentage points from the prior year.

Net Margin

-36.4%

YoY-25.3pp

5Y CAGR-7.9pp

10Y CAGR+3.3pp

Sanara Medtech Inc's net profit margin was -36.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 25.3 percentage points from the prior year.

Return on Equity

-632.5%

YoY-608.0pp

5Y CAGR-560.3pp

Sanara Medtech Inc's ROE was -632.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 608.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.1M

YoY-11.1%

5Y CAGR+163.2%

Sanara Medtech Inc invested $5.1M in research and development in fiscal year 2025. This represents a decrease of 11.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$4.6M

YoY+2147.1%

5Y CAGR+53.4%

10Y CAGR+96.7%

Sanara Medtech Inc invested $4.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 2147.1% from the prior year.

SMTI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$103.1M+19.0%	$86.7M+33.4%	$65.0M+41.8%	$45.8M+89.9%	$24.1M+54.9%	$15.6M
Cost of Revenue	$7.5M-7.6%	$8.1M+3.7%	$7.9M+23.5%	$6.4M+175.2%	$2.3M+43.0%	$1.6M
Gross Profit	$95.6M+21.7%	$78.5M+37.4%	$57.1M+44.7%	$39.5M+80.8%	$21.8M+56.3%	$14.0M
R&D Expenses	$5.1M-11.1%	$5.7M+38.0%	$4.1M+22.7%	$3.4M+502.7%	$559K+1290.2%	$40K
SG&A Expenses	$78.7M+2.8%	$76.6M+34.3%	$57.0M+24.0%	$46.0M+63.9%	$28.1M+50.2%	$18.7M
Operating Income	$7.3M+208.8%	-$6.7M-59.3%	-$4.2M+66.3%	-$12.5M-69.7%	-$7.4M-46.5%	-$5.0M
Interest Expense	$6.8M+116.1%	$3.1M+557.5%	$476K+67.1%	$285K+39948.7%	$711-93.8%	$12K
Income Tax	$48K+200.0%	-$48K	N/A	-$5.8M	N/A	$0
Net Income	-$37.6M-288.7%	-$9.7M-124.6%	-$4.3M+45.8%	-$7.9M-0.2%	-$7.9M-78.2%	-$4.4M
EPS (Diluted)	$-4.36-282.5%	$-1.14-119.2%	$-0.52+48.0%	$-1.00	N/A	$-0.76

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$26.3M+1.9%	$25.8M+10.2%	$23.4M-10.9%	$26.3M+21.4%	$21.7M+7.5%	$20.2M+8.8%	$18.5M+4.8%	$17.7M
Cost of Revenue	$1.9M-3.3%	$1.9M+5.6%	$1.8M-18.4%	$2.2M+12.9%	$2.0M-0.8%	$2.0M+6.3%	$1.9M+5.7%	$1.8M
Gross Profit	$24.5M+2.4%	$23.9M+10.6%	$21.6M-10.2%	$24.1M+22.2%	$19.7M+8.4%	$18.2M+9.0%	$16.6M+4.7%	$15.9M
R&D Expenses	$1.0M-18.1%	$1.3M+12.9%	$1.1M-62.7%	$3.0M+281.1%	$784K-20.5%	$986K+4.2%	$946K+45.2%	$652K
SG&A Expenses	$19.9M-7.8%	$21.6M+0.5%	$21.4M-10.6%	$24.0M+37.7%	$17.4M-8.1%	$19.0M+17.1%	$16.2M-0.9%	$16.3M
Operating Income	$2.9M+9482.5%	-$31K+98.5%	-$2.1M+32.4%	-$3.1M-495.3%	$779K+127.0%	-$2.9M-88.3%	-$1.5M-577.8%	-$226K
Interest Expense	$1.8M+1.5%	$1.8M+36.0%	$1.3M+2.2%	$1.3M+39.0%	$928K+44.0%	$644K+141.0%	$267K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$30.4M-1409.7%	-$2.0M+42.9%	-$3.5M-129.2%	-$1.5M+46.2%	-$2.9M+18.4%	-$3.5M-98.6%	-$1.8M-643.8%	-$237K
EPS (Diluted)	$-3.40-1378.3%	$-0.23+43.9%	$-0.41	N/A	$-0.34+17.1%	$-0.41-95.2%	$-0.21	N/A

SMTI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$72.9M-17.2%	$88.1M+19.3%	$73.9M+21.0%	$61.0M+67.7%	$36.4M+270.4%	$9.8M
Current Assets	$33.5M+0.7%	$33.3M+75.2%	$19.0M-7.8%	$20.6M-16.2%	$24.6M+449.0%	$4.5M
Cash & Equivalents	$16.6M+4.4%	$15.9M+208.5%	$5.1M-42.5%	$9.0M-52.0%	$18.7M+3996.2%	$455K
Inventory	$3.9M+43.4%	$2.8M-41.6%	$4.7M+32.9%	$3.5M+73.3%	$2.0M+78.4%	$1.1M
Accounts Receivable	$12.0M	N/A	N/A	$6.8M+137.9%	$2.9M	$0
Goodwill	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M	N/A	N/A
Total Liabilities	$67.0M+36.3%	$49.2M+67.9%	$29.3M+51.6%	$19.3M+209.3%	$6.2M+56.7%	$4.0M
Current Liabilities	$18.6M+21.8%	$15.3M+11.1%	$13.8M+7.5%	$12.8M+112.6%	$6.0M+70.1%	$3.5M
Long-Term Debt	$46.0M+49.8%	$30.7M+236.8%	$9.1M	N/A	N/A	N/A
Total Equity	$5.9M-84.9%	$39.4M-12.1%	$44.8M+7.2%	$41.8M+36.5%	$30.6M+398.2%	$6.2M
Retained Earnings	-$75.3M-99.3%	-$37.8M-34.8%	-$28.0M-19.8%	-$23.4M-53.6%	-$15.2M-116.6%	-$7.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$71.1M-28.0%	$98.8M+2.5%	$96.4M+9.4%	$88.1M-0.5%	$88.5M+20.7%	$73.4M+3.5%	$70.9M-4.0%	$73.9M
Current Assets	$31.2M-7.3%	$33.7M-8.6%	$36.8M+10.6%	$33.3M+4.4%	$31.9M+53.3%	$20.8M+21.1%	$17.2M-9.6%	$19.0M
Cash & Equivalents	$14.9M-11.9%	$17.0M-18.0%	$20.7M+30.3%	$15.9M-2.5%	$16.3M+164.7%	$6.2M+117.5%	$2.8M-45.1%	$5.1M
Inventory	$3.4M-3.6%	$3.5M+11.2%	$3.2M+14.8%	$2.8M-8.5%	$3.0M-15.6%	$3.6M-15.7%	$4.2M-10.4%	$4.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M
Total Liabilities	$64.9M+2.5%	$63.4M+6.1%	$59.7M+21.4%	$49.2M+0.2%	$49.1M+53.5%	$32.0M+14.6%	$27.9M-4.7%	$29.3M
Current Liabilities	$17.4M+16.7%	$14.9M+12.0%	$13.3M-13.1%	$15.3M+6.6%	$14.3M+24.0%	$11.6M-9.3%	$12.7M-7.4%	$13.8M
Long-Term Debt	$45.1M+2.0%	$44.2M+1.9%	$43.4M+41.4%	$30.7M+2.0%	$30.1M+109.3%	$14.4M+63.9%	$8.8M-3.8%	$9.1M
Total Equity	$6.1M-82.6%	$35.4M-3.5%	$36.7M-6.9%	$39.4M-1.0%	$39.8M-4.6%	$41.7M-3.7%	$43.3M-3.4%	$44.8M
Retained Earnings	-$73.7M-70.2%	-$43.3M-4.8%	-$41.3M-9.3%	-$37.8M-4.2%	-$36.2M-8.6%	-$33.4M-11.7%	-$29.9M-6.6%	-$28.0M

SMTI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$6.8M+28634.4%	-$24K+99.3%	-$3.2M+41.6%	-$5.6M-15.4%	-$4.8M-19.3%	-$4.0M
Capital Expenditures	$4.6M+2147.1%	$206K-22.4%	$265K+80.4%	$147K-14.5%	$172K-68.4%	$544K
Free Cash Flow	$2.2M+1041.1%	-$230K+93.5%	-$3.5M+38.4%	-$5.7M-14.3%	-$5.0M-8.9%	-$4.6M
Investing Cash Flow	-$15.0M-126.5%	-$6.6M+35.2%	-$10.2M-190.7%	-$3.5M+33.6%	-$5.3M-92.6%	-$2.7M
Financing Cash Flow	$8.9M-48.8%	$17.4M+80.1%	$9.6M+1636.8%	-$627K-102.2%	$28.3M+4446.9%	$622K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$2.2M-18.3%	$2.7M+233.3%	-$2.0M-314.5%	$932K-54.5%	$2.1M+245.2%	-$1.4M+11.4%	-$1.6M-87.9%	-$849K
Capital Expenditures	$1.1M-39.8%	$1.8M+2.2%	$1.7M+2286.9%	$72K+693.4%	$9K-84.5%	$59K-10.7%	$66K+21.3%	$54K
Free Cash Flow	$1.1M+23.7%	$903K+124.3%	-$3.7M-532.8%	$860K-57.9%	$2.0M+238.8%	-$1.5M+11.4%	-$1.7M-83.9%	-$903K
Investing Cash Flow	-$3.4M+12.9%	-$3.9M+24.2%	-$5.2M-3884.7%	-$130K+98.0%	-$6.4M-10718.3%	-$59K+10.7%	-$66K-21.3%	-$54K
Financing Cash Flow	-$775K+68.6%	-$2.5M-120.6%	$12.0M+1098.2%	-$1.2M-108.3%	$14.4M+201.1%	$4.8M+827.5%	-$659K-254.4%	-$186K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SMTI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	92.7%+2.1pp	90.6%+2.7pp	87.9%+1.8pp	86.1%-4.3pp	90.4%+0.8pp	89.6%
Operating Margin	7.1%+14.8pp	-7.8%-1.3pp	-6.5%+20.8pp	-27.3%+3.2pp	-30.6%+1.8pp	-32.3%
Net Margin	-36.4%-25.3pp	-11.2%-4.5pp	-6.6%+10.7pp	-17.3%+15.5pp	-32.8%-4.3pp	-28.5%
Return on Equity	-632.5%-608.0pp	-24.5%-14.9pp	-9.6%+9.4pp	-19.0%+6.9pp	-25.9%+46.4pp	-72.3%
Return on Assets	-51.5%-40.5pp	-11.0%-5.1pp	-5.8%+7.2pp	-13.0%+8.8pp	-21.8%+23.5pp	-45.2%
Current Ratio	1.80-0.4	2.18+0.8	1.38-0.2	1.61-2.5	4.09+2.8	1.27
Debt-to-Equity	7.74+7.0	0.78+0.6	0.20-0.3	0.46+0.3	0.20-0.4	0.65
FCF Margin	2.1%+2.4pp	-0.3%+5.1pp	-5.4%+7.0pp	-12.4%+8.2pp	-20.6%+8.7pp	-29.4%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	92.9%+0.4pp	92.5%+0.3pp	92.2%+0.7pp	91.5%+0.6pp	90.8%+0.8pp	90.0%+0.2pp	89.8%-0.1pp	89.9%
Operating Margin	11.2%+11.3pp	-0.1%+8.8pp	-8.9%+2.8pp	-11.7%-15.3pp	3.6%+17.9pp	-14.3%-6.0pp	-8.3%-7.0pp	-1.3%
Net Margin	-115.5%-107.7pp	-7.8%+7.2pp	-15.0%-9.2pp	-5.9%+7.3pp	-13.2%+4.2pp	-17.4%-7.9pp	-9.5%-8.2pp	-1.3%
Return on Equity	-494.6%-488.9pp	-5.7%+3.9pp	-9.6%-5.7pp	-3.9%+3.3pp	-7.2%+1.2pp	-8.4%-4.3pp	-4.1%-3.6pp	-0.5%
Return on Assets	-42.8%-40.7pp	-2.0%+1.6pp	-3.7%-1.9pp	-1.8%+1.5pp	-3.2%+1.5pp	-4.8%-2.3pp	-2.5%-2.2pp	-0.3%
Current Ratio	1.80-0.5	2.26-0.5	2.77+0.6	2.18-0.0	2.23+0.4	1.80+0.5	1.35-0.0	1.38
Debt-to-Equity	7.33+6.1	1.25+0.1	1.18+0.4	0.78+0.0	0.76+0.4	0.34+0.1	0.200.0	0.20
FCF Margin	4.2%+0.8pp	3.5%+19.4pp	-15.9%-19.1pp	3.3%-6.2pp	9.4%+16.7pp	-7.3%+1.7pp	-9.0%-3.9pp	-5.1%

Similar Companies

Angiodynamics ANGO

$425.0M

Embecta Corp EMBC

$524.1M

KESTRA MED TECHNOLOGIES LTD KMTS

$1.2B

Stereotaxis Ord STXS

$181.9M

Orasure Tech OSUR

$212.9M

Frequently Asked Questions

What is Sanara Medtech Inc's annual revenue?

Sanara Medtech Inc (SMTI) reported $103.1M in total revenue for fiscal year 2025. This represents a 19.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sanara Medtech Inc's revenue growing?

Sanara Medtech Inc (SMTI) revenue grew by 19% year-over-year, from $86.7M to $103.1M in fiscal year 2025.

Is Sanara Medtech Inc profitable?

No, Sanara Medtech Inc (SMTI) reported a net income of -$37.6M in fiscal year 2025, with a net profit margin of -36.4%.

What is Sanara Medtech Inc's EBITDA?

Sanara Medtech Inc (SMTI) had EBITDA of $11.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Sanara Medtech Inc have?

As of fiscal year 2025, Sanara Medtech Inc (SMTI) had $16.6M in cash and equivalents against $46.0M in long-term debt.

What is Sanara Medtech Inc's gross margin?

Sanara Medtech Inc (SMTI) had a gross margin of 92.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Sanara Medtech Inc's operating margin?

Sanara Medtech Inc (SMTI) had an operating margin of 7.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Sanara Medtech Inc's net profit margin?

Sanara Medtech Inc (SMTI) had a net profit margin of -36.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Sanara Medtech Inc's return on equity (ROE)?

Sanara Medtech Inc (SMTI) has a return on equity of -632.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sanara Medtech Inc's free cash flow?

Sanara Medtech Inc (SMTI) generated $2.2M in free cash flow during fiscal year 2025. This represents a 1041.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sanara Medtech Inc's operating cash flow?

Sanara Medtech Inc (SMTI) generated $6.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sanara Medtech Inc's total assets?

Sanara Medtech Inc (SMTI) had $72.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Sanara Medtech Inc's capital expenditures?

Sanara Medtech Inc (SMTI) invested $4.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Sanara Medtech Inc spend on research and development?

Sanara Medtech Inc (SMTI) invested $5.1M in research and development during fiscal year 2025.

How many shares does Sanara Medtech Inc have outstanding?

Sanara Medtech Inc (SMTI) had 9M shares outstanding as of fiscal year 2025.

What is Sanara Medtech Inc's current ratio?

Sanara Medtech Inc (SMTI) had a current ratio of 1.80 as of fiscal year 2025, which is generally considered healthy.

What is Sanara Medtech Inc's debt-to-equity ratio?

Sanara Medtech Inc (SMTI) had a debt-to-equity ratio of 7.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sanara Medtech Inc's return on assets (ROA)?

Sanara Medtech Inc (SMTI) had a return on assets of -51.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sanara Medtech Inc's Altman Z-Score?

Sanara Medtech Inc (SMTI) has an Altman Z-Score of 1.96, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Sanara Medtech Inc's Piotroski F-Score?

Sanara Medtech Inc (SMTI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sanara Medtech Inc's earnings high quality?

Sanara Medtech Inc (SMTI) has an earnings quality ratio of -0.18x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Sanara Medtech Inc cover its interest payments?

Sanara Medtech Inc (SMTI) has an interest coverage ratio of 1.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Sanara Medtech Inc?

Sanara Medtech Inc (SMTI) scores 28 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.